Results 31 to 40 of about 69,008 (285)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment

Molecular Imaging, 2014
Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be ...
Sietske B.M. Gaykema, Johan R. de Jong, Patrick J. Perik, Adrienne H. Brouwers, Carolien P. Schröder, Thijs H. Oude Munnink, Alphons H.H. Bongaerts, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge   +8 more
doaj   +1 more source

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics

Journal of Ovarian Research, 2010
Background Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and
Wilken Jason A, Webster Kristy T, Maihle Nita J   +2 more
doaj   +1 more source

Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

Biomedicines, 2022
Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment.
Dmitrii Kamashev, Nina Shaban, Maria Suntsova, Mikhail Raevskiy, Victor Efimov, Aleksey Moisseev, Maxim Sorokin, Anton Buzdin   +7 more
doaj   +1 more source

Retracted: Trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in gastric cancer

FEBS Open Bio, 2018
Gastric cancer (GC) is one of the most prevalent cancers worldwide. Trastuzumab has been approved for the treatment of metastatic GC, gastroesophageal junction cancer, and breast cancer.
Linghe Luo, Haiyan Liu, Qian Xi
doaj   +1 more source

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Pharmaceuticals, 2021
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is
Steven Simoens, Arnold G. Vulto, Pieter Dylst   +2 more
doaj   +1 more source

miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer

Cell Death and Disease, 2021
Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive.
Jing Guo, Xuxian Zhong, Qinglin Tan, Shengnan Yang, Jiaqi Liao, Jinke Zhuge, Ziyang Hong, Qiong Deng, Qiang Zuo   +8 more
doaj   +1 more source

JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12

Cell Death Discovery, 2021
Breast cancer is the most common cancer worldwide. JWA is a microtubule-associated protein that has been identified as a tumor suppressor, and its downregulation in tumors is an independent adverse prognostic factor.
Yan Liang, Chao Qian, Yinghong Xie, Xiang Huang, Junjie Chen, Yanlin Ren, Ziyi Fu, Yongfei Li, Tianyu Zeng, Fan Yang, Jianwei Zhou, Wei Li, Yongmei Yin, Changqing Wang   +13 more
doaj   +1 more source

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Frontiers in Oncology, 2022
Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer.
Zhen-hao Wang, Zhen-hao Wang, Zhuo-qun Zheng, Shi−cheng Jia, Shu-ni Liu, Xiao-fen Xiao, Xiao-fen Xiao, Guan-yuan Chen, Guan-yuan Chen, Wei-quan Liang, Wei-quan Liang, Xiao-feng Lu, Xiao-feng Lu   +12 more
doaj   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Efficient Preparation of Homogenous Antibody Conjugates via Glycosite‐Specific Transglycosylation Enabled by Readily Available Glycosyl Donors

Angewandte Chemie, EarlyView.
A streamlined platform for glycosite‐specific antibody conjugation is enabled by LacNAc‐derived cyclic acetal donors, which can be prepared in only two steps and used directly in single‐enzyme Endo S2‐mediated transglycosylation. The platform supports the broad construction of homogeneous gsADCs and gsDACs, with donor 7 producing glycoengineered ...
Deqin Cai, Yuan Zhao, Gaoyuan Lu, Chunrong Li, Yichong Lao, Ramesh Mudududdla, Jiahao Zhang, Peijing Jia, Penghsuan Huang, Wenxin Wu, Thao‐Vy T. Nguyen, Xuhui Huang, Lingjun Li, Weiping Tang   +13 more
wiley   +2 more sources